The purpose of this review is to offer an overview of the compounds showing promising activities in PBC, and above all, it aims to highlight the chemical characteristics of new steroid FXR agonists in order to clarify their structure-activity relationship. The gene discussed is NR1H4; the disease is primary biliary cholangitis.